



899 North Capitol St. NE – 2nd Floor
Washington, DC 20002
January 25, 2017
8:30 am – 4:45 pm

BOARD OF MEDICINE

OPEN SESSION AGENDA

BoMed Mission Statement:

“To **protect** and enhance the health, safety, and well-being of District of Columbia residents by **promoting** evidence-based best practices in health regulation, high standards of quality care and implementing policies that **prevent** adverse events.”

BOARD MEETING PARTICIPANTS:

BOARD MEMBERS:	
Janis Orłowski, MD (JO)	
Marc Rankin, MD (MR)	
Anitra Denson, MD (AD)	
Lawrence Manning, MD (LM)	
Andrea Anderson, MD (AA)	
Thomas Dawson, Esq. (TD)	
Jeffrey Smith, MD (JS)	
Kelly Ann Colden, MD (KC)	
Terrence Straub (TS)	
Treazure Johnson, Esq. (TJ)	
Vikisha Fripp, MD (VF)	
David Wessel, MD (DW)	
Thomas Smith (TS2)	
BOARD STAFF:	
Frank Meyers, JD – Executive Director	
Lisa Robinson – Health Licensing Specialist	
Mary Harris – Health Licensing Specialist	
Aisha Nixon – Health Licensing Specialist	
Angela Braxton – Health Licensing Specialist	
Shivangi Bhatt – Temp/ Contractor	
Emilia Moran – Investigator	
Diane Moorer – IT Support	
LEGAL STAFF:	
Suzanne Fenzel, Esq. – Board Attorney Advisor	
Ajay Gohil, Esq. – Interim Board Attorney Advisor	
Christopher Boone, Esq. – Law Clerk	

The agenda begins on the next page with the Open Session items.¹

¹ The order in which the following agenda items are listed does not necessarily reflect the order in which the items will be discussed during the meeting.
BOARD OF MEDICINE OPEN SESSION AGENDA
January 25, 2017

OPEN SESSION

8:30 am to 10:30 am

1. Call to Order
2. Introduction of Board Members
3. Introduction of Board Staff

APPROVAL OF MINUTES, CONSENT AGENDA AND STAFF REPORTS	
OS-17-01-001 ALL	<p><u>BOARD/DEPARTMENT REPORT</u></p> <p>A. BOARD CHAIR’S REPORT</p> <p>B. EXECUTIVE DIRECTOR’S REPORT</p> <p style="padding-left: 40px;">a. New Board Member Introduction The Mayor’s Office of Talent and Appointments (MOTA) held a swearing in ceremony on January 17, 2017, during which time Mr. Thomas Smith was sworn in as a new consumer member to the Board.</p> <p style="padding-left: 40px;">b. Licensure Census Update The Executive Director will provide an update on the number of current active licenses issued by the Board of Medicine, outlined by profession.</p> <p>C. BOARD ATTORNEY’S REPORT</p>
OS-17-01-002 ALL	<p><u>OPEN SESSION MINUTES</u></p> <p>Board Action: Consideration of the Open Session minutes from the December 28, 2016 meeting.</p> <p>Background: The Open Session Minutes are a record of the Board’s past meeting(s), describing the events, list of attendees, a statement of the issues considered and related responses or decisions of the Board.</p>
OS-17-01-003 ALL	<p><u>OPEN CONSENT AGENDA</u></p> <p>Board Action: Consideration of the current January 25, 2017 Open Consent Agenda items for purposes of review and/or ratification of Board actions taken since the last Board meeting.</p> <p>Background: The Open Consent Agenda is a record of the decisions and/or actions taken by the Board or its staff since the last meeting of the Board.</p>

MISC. ITEMS FOR DISCUSSION

OS-17-01-004	<p><u>COLLABORATIVE PRACTICE REGULATIONS</u></p> <p>Board Action: To review the proposed rules from the Board of Pharmacy regarding Collaborative practice as set forth in DC Code § 3-1202.08(h)(2).</p> <p>Background: DC Code § 3-1202.08(h)(2) states that the Board of Pharmacy and the Board of Medicine shall jointly develop and issue regulations governing the implementation and use of collaborative practice agreements between a licensed pharmacist and a licensed physician covering the following:</p> <ol style="list-style-type: none">1. Specification of the drug therapy to be provided and any tests that may be necessarily incident to its provision;2. The conditions for initiating, modifying, or discontinuing a drug therapy; and3. Directions concerning the monitoring of a drug therapy, including the conditions that would warrant a modification to the dose, dosage regime, or dosage form of the drug therapy; and4. Establish policies and procedures for approving, disapproving, and revoking collaborative practice agreements. <p>The Board of Pharmacy previously drafted and then published for comment regulations governing collaborative practice. The comment period has finished, and while the Board of Pharmacy has already reviewed and made changes to the existing rules based on the provided comments, the Board of Medicine still needs to review and give its approval.</p> <p>A copy of the most recent draft of the collaborative practice regulations with noted changes, along with a table of comments, are being provided for the Board's review and guidance.</p>	
OS-17-01-005	<p><u>FSMB OPIOD PRESCRIBING GUIDELINES</u></p> <p>Board Action: To review the draft Federation of State Medical Board (FSMB) <i>Model Policy for the Use of Opioid Analgesics in the Treatment of Chronic Pain</i>, and possible provide stakeholder review and comment.</p> <p>Background: In 2015, FSMB established a workgroup to conduct a thorough review and analysis of existing policies, including both state and federal policies, on the prescribing of opioids in the treatment of pain. The workgroup has now completed it's review and issues it's draft policy document, for which it is seeking stakeholder review and comment.</p>	

End of Open Session.

TO BE READ BY BOARD CHAIR:

This concludes the Public Open Session of the meeting and pursuant to DC Official Code § 2-575(b), the Board will now move into the Closed Executive Session portion of the meeting to discuss the following:

- 1. To consult with an attorney to obtain legal advice and to preserve the attorney-client privilege between an attorney and a public body, or to approve settlement agreements pursuant to § 2-575(b)(4)(a);**
- 2. Preparation, administration, or grading of scholastic, licensing, or qualifying examinations pursuant to section § 2-575(b)(6);**
- 3. To discuss disciplinary matters pursuant to section § 2-575(b)(9);**
- 4. To plan, discuss, or hear reports concerning ongoing or planned investigation of alleged criminal or civil misconduct or violations of law or regulations, if disclosure to the public would harm the investigation pursuant to section § 2-575(b) (14).**

Based on the forgoing, is there a motion to go into Closed Executive Session?